Researcher
Jurgen Joossens
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Tech Transfer Office (TTO) (Research group)
Responsible
From1 Nov 2016 → Today - Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2005 → 31 Oct 2016
Projects
11 - 20 of 22
- IOF Valorisation Life SciencesFrom1 Jan 2021 → 16 Jul 2021Funding: IOF - mandates
- Valorisation of EPS (extracellular polymeric substances) from sludge by use as curing compound for concrete or additive in adhesives.From1 Jan 2020 → 30 Jun 2021Funding: IOF - technology validation in lab
- IOF Valorisation Life Sciences.From20 Aug 2017 → TodayFunding: IOF - mandates
- IOF Valorisation Life Sciences.From1 May 2017 → 31 Dec 2020Funding: IOF - mandates, IOF - Industrial Research Fund
- IOF Valorisation Social Sciences and Humanities.From1 Apr 2017 → TodayFunding: IOF - mandates
- Medicinal Chemistry-Drug Discovery (ADDN).From1 Jan 2015 → 31 Dec 2020Funding: IOF - mandates, IOF - Industrial Research Fund
- Creation of a preclinical platform at the UA for testing novel therapeutic approaches against ocular surface diseases.From1 Jan 2014 → 31 Dec 2015Funding: IOF - Industrial Research Fund
- Serthera: locking and monitoring of serine protease activity as the technological base for development of new and innovative drug candidates.From1 Jun 2013 → 31 Aug 2014Funding: IWT / VLAIO personal funding - innovation mandates
- Development of uPA probes as tools for imaging and diagnostic applications.From1 May 2011 → 30 Apr 2013Funding: IOF - Industrial Research Fund
- Topically applicable long-lasting glucocorticoid receptor agonists for the treatment of inflammatory skin diseases.From15 Apr 2011 → 14 Apr 2012Funding: Industrial enterprises, IOF - Industrial Research Fund
Publications
1 - 10 of 50
- The effect of serine protease inhibitors on visceral pain in different rodent models with an intestinal insult(2022)
Authors: Hannah Ceuleers, Nikita Hanning, Michelle De bruyn, Joris De Man, Heiko De Schepper, Qian Li, Liansheng Liu, Steven Abrams, Annemieke Smet, Jurgen Joossens, et al.
Pages: 1 - 17 - Local colonic administration of a serine protease inhibitor improves post-inflammatory visceral hypersensitivity in rats(2021)
Authors: Nikita Hanning, Michelle De bruyn, Hannah Ceuleers, Tim Boogaerts, Maya Berg, Annemieke Smet, Heiko De Schepper, Jurgen Joossens, Alexander van Nuijs, Joris De Man, et al.
- The effect of a novel serine protease inhibitor on inflammation and intestinal permeability in a murine colitis transfer model(2021)
Authors: Hanne Van Spaendonk, Hannah Ceuleers, Annemieke Smet, Maya Berg, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Anne-Marie Lambeir, Joris De Man, Ingrid De Meester, et al.
Pages: 1 - 13 - A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation(2020)
Authors: Cedric Joossen, Adrienn Baán, Carlos Moreno Cinos, Jurgen Joossens, Nathalie Cools, Ellen Lanckacker, Lieve Moons, Kim Lemmens, Anne-Marie Lambeir, Erik Fransen, et al.
Pages: 1 - 14 - α-amino diphenyl phosphonates as novel inhibitors of Escherichia coli ClpP protease(2019)
Authors: Carlos Moreno Cinos, Elisa Sassetti, Irene Garcìa Salado, Gesa Witt, Siham Benramdane, Laura Reinhardt, Cristina D. Cruz, Jurgen Joossens, Pieter Van Der Veken, Heike Broetz-Oesterhe, et al.
Pages: 774 - 797 - The effect of pharmacological inhibition of Serine Proteases on neuronal networks in vitro(2019)
Authors: Sebastiaan Van De Vijver, Stephan Missault, Jeroen Van Soom, Pieter Van Der Veken, Koen Augustyns, Jurgen Joossens, Stefanie Dedeurwaerdere, Michele Giugliano
Pages: 1 - 23 - Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome(2018)
Authors: Hannah Ceuleers, Nikita Hanning, Leen Heirbaut, Samuel Van Remoortel, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Michelle De bruyn, Joris De Man, Jean-Pierre Timmermans, et al.
Pages: 3516 - 3533 - Novel triazine dimers with potent antitrypanosomal activity(2018)
Authors: Muthusamy Venkatraj, Irene Garcìa Salado, Jan Heeres, Jurgen Joossens, Guy Caljon, Louis Maes, Pieter Van Der Veken, Koen Augustyns
Pages: 306 - 319 - Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury(2017)
Authors: Sofie Martens, Manhyung Jeong, Wulf Tonnus, Friederike Feldmann, Sam Hofmans, Vera Goossens, Nozomi Takahashi, Jan Hinrich Braesen, Eun-Woo Lee, Pieter Van Der Veken, et al.
- Decreased levels of active uPA and KLK8 assessed by $\left[^{111}In\right]$MICA-401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy(2017)
Authors: Stephan Missault, Lore Peeters, Halima Amhaoul, David Thomae, Annemie Van Eetveldt, Barbara Favier, Anagha Thakur, Jeroen Van Soom, Asla Pitkanen, Koen Augustyns, et al.
Pages: 1615 - 1625
Patents
1 - 10 of 10
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- Triazines with suitable spacers for treatment and/or prevention of HIV infections (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)